Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

240P - A multinational real-world study on HR+, HER2- early stage breast cancer patients' disease awareness, satisfaction, and involvement in treatment decisions

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Alex Rider

Citation

Annals of Oncology (2020) 31 (suppl_4): S303-S339. 10.1016/annonc/annonc267

Authors

A. Rider1, M. Method2, R. Williams1, J. Piercy1, E. Clayton1, J. Brown3

Author affiliations

  • 1 Oncology, Adelphi Real World - Adelphi Group, SK10 5JB - Bollington/GB
  • 2 Gporwe, Eli Lilly and Company, 46285 - Indianapolis/US
  • 3 Gporwe Oncology, Eli Lilly and Company, GU20 6PH - Windlesham/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 240P

Background

Among patients [pts] diagnosed with early-stage HR+, HER2- breast cancer (BC), this study aimed to describe awareness, information sources, satisfaction and degree of involvement in treatment decisions.

Methods

A multinational (France, Germany, Italy, Spain, UK, Japan and US) survey of pts diagnosed with stage I-III HR+, HER2- BC was conducted from June to October 2019. Pts identified by their physician were invited to complete a pen and paper questionnaire with questions on awareness of 4 aspects of their BC (stage, nodal status, HER2 and HR status), information sources used, satisfaction, and involvement in treatment decisions for their BC.

Results

1152 pts completed the questionnaire (mean age 59 years; 33% with degreed education; 31% pre/peri-menopausal and 1% male; Stage at diagnosis: I 30%, II 48%, III 22%). UK pts were most aware of all 4 aspects of their BC (58%), Italian (18%) and Japanese (20%) pts the least aware. Pts reporting being actively involved in treatment decisions was highest in Germany (68%) and least in Spain (30%). Awareness of all 4 aspects of their BC was highest among pts with degreed education (48%), with 63% reporting active involvement in treatment decisions; and lowest amongst those with no degreed education (30%), with 47% reporting active involvement. Pre/peri-menopausal pts were most aware of all 4 aspects of their BC (46%) (post-menopausal pts (31%). 90% of all pts cited their doctor as an information source. The second most common source was the internet amongst pre/peri-menopausal pts (57%) and family/friends for post-menopausal pt (39%). 71% who very much agree with the statement ‘I am satisfied with how well I am coping with my illness’ feel they are actively involved in treatment decisions compared to 44% of who do not agree at all with the statement.

Conclusions

A high proportion of pts satisfied with how they were coping with their illness were actively involved in their treatment decisions. Knowledge and involvement were highest in pts with degreed education and amongst pre/peri-menopausal pts, suggesting there may be a need to raise knowledge and awareness in older pts or those without a degreed education.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Adelphi Real World.

Funding

Eli Lilly and Company.

Disclosure

A. Rider: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. M. Method: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company. R. Williams: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. J. Piercy: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. E. Clayton: Honoraria (institution), Eli Lilly have paid Adelphi Real World a fee for conducting this research and drafting this abstract: Eli Lilly and Company. J. Brown: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.